IceCure Medical (NASDAQ:ICCM) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $2.50 price target on the stock.

IceCure Medical Stock Up 0.5 %

Shares of NASDAQ:ICCM opened at $1.11 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.27. The stock has a market cap of $61.61 million, a price-to-earnings ratio of -3.83 and a beta of 0.37. The company has a 50 day moving average of $1.32 and a 200-day moving average of $0.99. IceCure Medical has a one year low of $0.48 and a one year high of $1.66.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Thursday, March 27th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. On average, sell-side analysts forecast that IceCure Medical will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC lifted its position in IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the period. Geode Capital Management LLC owned approximately 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. Institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.